We are live on ! Find out more
FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 151.58%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$49.1M
Cap. Flow
+$130M
Cap. Flow %
10.05%
Top 10 Hldgs %
55.9%
Holding
47
New
6
Increased
12
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$29.3M
2
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
+$28.6M
3
SLN
Silence Therapeutics
SLN
+$20.5M
4
KALV
KalVista Pharmaceuticals
KALV
+$18.3M
5
MRUS
Merus
MRUS
+$15.8M

Top Sells

Rank Stock Value
1
TRIL
Trillium Therapeutics Inc.
TRIL
+$55M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$20.4M
3
BLU
BELLUS Health Inc.
BLU
+$2.65M
4
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$1.95M
5
FRLN
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
+$1.88M

Sector Composition

Rank Sector Weight
1 Healthcare 98.85%
2 Miscellaneous 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.13B
$175M 13.47%
8,434,232
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$723M
$115M 8.82%
5,827,415
– –
IMGO
3
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
$70.4M 5.42%
2,971,274
– –
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.8B
$60.7M 4.67%
2,772,062
+1,583,927
+133% +$29.3M
GRTS
5
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$60M 4.62%
4,667,242
– –
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$6.08B
$56.9M 4.38%
3,566,912
– –
PCVX icon
7
Vaxcyte
PCVX
$9.1B
$54.9M 4.23%
2,309,554
– –
KRYS icon
8
Krystal Biotech
KRYS
$10.6B
$53.9M 4.15%
771,250
– –
PRDS
9
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$40.2M 3.1%
+2,457,507
New +$28.6M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$9B
$39.3M 3.03%
1,384,293
+532,987
+63% +$13.1M
KDNY
11
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$38.7M 2.98%
2,371,918
+700,000
+42% +$9.96M
BCYC
12
Bicycle Therapeutics
BCYC
$303M
$33.8M 2.6%
555,240
+112,360
+25% +$6.2M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$3.74B
$33.4M 2.57%
1,747,622
-926,677
-35% -$20.4M
TARS icon
14
Tarsus Pharmaceuticals
TARS
$3.16B
$31.9M 2.45%
1,417,157
– –
PASG icon
15
Passage Bio
PASG
$13.9M
$31.8M 2.45%
250,461
– –
ANAB icon
16
AnaptysBio
ANAB
$1.7B
$31.3M 2.41%
899,700
– –
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$30.7M 2.37%
1,838,402
– –
VRDN icon
18
Viridian Therapeutics
VRDN
$2.71B
$29.8M 2.29%
1,505,200
– –
SRRA
19
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$27.5M 2.12%
1,264,861
+460,194
+57% +$10.1M
STRO icon
20
Sutro Biopharma
STRO
$353M
$26.4M 2.04%
177,648
+30,782
+21% +$5.51M
ALPN
21
DELISTED
Alpine Immune Sciences Inc
ALPN
$24.7M 1.9%
1,784,913
+13,069
+0.7% +$162K
SLN
22
Silence Therapeutics
SLN
$836M
$21.2M 1.63%
+886,173
New +$20.5M
AUTL
23
Autolus Therapeutics
AUTL
$628M
$19.4M 1.5%
3,746,857
+216,200
+6% +$1.3M
MRUS
24
DELISTED
Merus
MRUS
$17.8M 1.37%
+559,179
New +$15.8M
REPL icon
25
Replimune Group
REPL
$1.47B
$17.6M 1.36%
650,862
+158,864
+32% +$4.75M
1
2

Similar funds

ACMV
August Capital Management VI Palo Alto, California $1.39M AUM
FRCMI
First Round Capital Management III Philadelphia, Pennsylvania $418K AUM
DB
DCVC Bio Palo Alto, California $313K AUM
NAM
Newfleet Asset Management Hartford, Connecticut $2.05M AUM 27.28% 1-Year Est. Return
AP
Atlas Principals Charlotte, North Carolina $2.19M AUM 56.71% 1-Year Est. Return
ID
Inspire Developers Forest Hills, New York $4.07M AUM
CI
CMT Investments Chicago, Illinois $5M AUM 15.27% 1-Year Est. Return
DIF
Discovery Investment Fund Singapore $6.98M AUM

Frazier Management's Q4 2021 Portfolio in Review

As of Q4 2021, Frazier Management held 47 positions worth $1.3B, up 3.9% from $1.25B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Frazier Management deployed $130M of net new capital in Q4 2021, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $20.4M trimmed.

  • Frazier Management's largest Q4 2021 buy was Pardes Biosciences, Inc. Common Stock: 2,457,507 shares worth $40.2M.
  • Frazier Management added most to Syndax Pharmaceuticals in Q4 2021, an estimated $29.3M increase.
  • Frazier Management's biggest Q4 2021 reduction was Iovance Biotherapeutics, cutting an estimated $20.4M.
  • Frazier Management fully exited Trillium Therapeutics Inc. in Q4 2021, selling an estimated $55M.
  • Frazier Management's ten largest holdings make up 56% of its $1.3B portfolio in Q4 2021.
  • Frazier Management opened 6 new positions and closed 4 in Q4 2021.
  • Frazier Management's portfolio value rose 3.9% quarter-over-quarter to $1.3B.

Based on Frazier Management's 13F filing for Q4 2021, filed 8 Feb 2022.